Alzamend Neuro Inc Financials
This page shows Alzamend Neuro Inc (ALZN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Development spending and overhead consume cash while external financing increasingly supports a shrinking, more leveraged balance sheet
In FY2026, operating cash flow of-$8.1M was less negative than net loss of-$8.8M . The ordering reversed in FY2025, so earnings and cash demand briefly diverged before reconverging; cash conversion remains the practical constraint.
The 2026 cost base was dominated by SG&A and R&D, which together nearly matched the operating loss at
External financing supplied
Financial Health Signals
Alzamend Neuro Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Alzamend Neuro Inc passes 1 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Alzamend Neuro Inc reported a net loss of $8.8M while operations used $8.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Alzamend Neuro Inc reported an operating loss of $8.8M against $7K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Alzamend Neuro Inc's EBITDA was -$8.7M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 94.7% from the prior year.
Alzamend Neuro Inc reported -$8.8M in net income in fiscal year 2026. This represents a decrease of 94.3% from the prior year.
Not reported for fiscal year 2026.
Cash & Balance Sheet
Alzamend Neuro Inc held $711K in cash as of fiscal year 2026; long-term debt is not reported for that period.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
Margins & Returns
Alzamend Neuro Inc's ROE was -1196.4% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is down 1082.6 percentage points from the prior year.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
Capital Allocation
Alzamend Neuro Inc invested $3.6M in research and development in fiscal year 2026. This represents an increase of 156.5% from the prior year.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
ALZN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $1.3M+625.3% | $176K-89.9% | $1.7M | N/A | $447K+43.7% | $311K+50.6% | $207K |
| SG&A Expenses | N/A | $919K+11.8% | $822K-14.3% | $959K | N/A | $590K-43.6% | $1.0M+38.5% | $756K |
| Operating Income | N/A | -$2.2M-120.2% | -$998K+63.0% | -$2.7M | N/A | -$1.0M+23.6% | -$1.4M-41.1% | -$962K |
| Interest Expense | N/A | $1K-49.5% | $3K+6.7% | $2K | N/A | $2K-42.2% | $3K-70.9% | $12K |
| Net Income | N/A | -$2.2M-119.7% | -$1.0M+63.0% | -$2.7M | N/A | -$1.0M+23.7% | -$1.4M-39.7% | -$974K |
| EPS (Diluted) | -$0.74-27.6% | -$0.58-93.3% | -$0.30 | -$1.28+28.1% | -$1.78 | -$1.75 | -$3.61 | -$11.42 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
ALZN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.1M-48.6% | $4.0M-20.6% | $5.1M-19.5% | $6.3M+37.4% | $4.6M+10.2% | $4.2M-16.6% | $5.0M+199.9% | $1.7M |
| Current Assets | $1.8M-52.3% | $3.7M-21.6% | $4.7M-20.4% | $5.9M+41.9% | $4.2M+5.8% | $3.9M-17.2% | $4.8M+236.6% | $1.4M |
| Cash & Equivalents | $711K-73.8% | $2.7M-39.0% | $4.4M-20.8% | $5.6M+42.3% | $3.9M+17.6% | $3.4M-18.0% | $4.1M+242.8% | $1.2M |
| Total Liabilities | $1.3M-27.5% | $1.9M+158.9% | $717K-27.0% | $983K+54.9% | $635K-12.5% | $726K-42.2% | $1.3M-56.5% | $2.9M |
| Total Equity | $733K-66.7% | $2.2M-49.7% | $4.4M-18.1% | $5.3M+34.7% | $4.0M+15.0% | $3.4M-8.1% | $3.8M+409.6% | -$1.2M |
| Retained Earnings | -$67.3M-4.5% | -$64.4M-3.5% | -$62.2M-1.6% | -$61.2M-4.6% | -$58.5M-2.0% | -$57.4M-1.7% | -$56.4M-2.6% | -$55.0M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Current Liabilities, Long-Term Debt.
ALZN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.8M-61.1% | -$1.7M-48.2% | -$1.2M+50.4% | -$2.4M-243.1% | -$689K+51.6% | -$1.4M+58.1% | -$3.4M-222.1% | -$1.1M |
| Investing Cash Flow | N/A | N/A | N/A | N/A | -$210K | $0 | $0+100.0% | -$90K |
| Financing Cash Flow | $795K | $0 | $0-100.0% | $4.0M+170.9% | $1.5M+116.2% | $689K-89.1% | $6.3M+220.8% | $2.0M |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
ALZN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | N/A | -100.0%-77.1pp | -22.9%+27.7pp | -50.6% | N/A | -30.1%+6.2pp | -36.3% | N/A |
| Return on Assets | N/A | -54.4%-34.8pp | -19.7%+23.1pp | -42.7% | N/A | -24.9%+2.3pp | -27.2%+31.2pp | -58.4% |
| Debt-to-Equity | 1.84+1.0x | 0.84+0.7x | 0.160.0x | 0.180.0x | 0.16-0.1x | 0.21-0.1x | 0.33 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Current Ratio, FCF Margin.
Similar Companies
Where Alzamend Neuro Inc Ranks
Frequently Asked Questions
Is Alzamend Neuro Inc profitable?
No, Alzamend Neuro Inc (ALZN) reported a net income of -$8.8M in fiscal year 2026.
What is Alzamend Neuro Inc's EBITDA?
Alzamend Neuro Inc (ALZN) had EBITDA of -$8.7M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is Alzamend Neuro Inc's return on equity (ROE)?
Alzamend Neuro Inc (ALZN) has a return on equity of -1196.4% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Alzamend Neuro Inc's operating cash flow?
Alzamend Neuro Inc (ALZN) recorded an outflow of $8.1M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are Alzamend Neuro Inc's total assets?
Alzamend Neuro Inc (ALZN) had $2.1M in total assets as of fiscal year 2026, including both current and long-term assets.
How much does Alzamend Neuro Inc spend on research and development?
Alzamend Neuro Inc (ALZN) invested $3.6M in research and development during fiscal year 2026.
What is Alzamend Neuro Inc's debt-to-equity ratio?
Alzamend Neuro Inc (ALZN) had a debt-to-equity ratio of 1.84 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Alzamend Neuro Inc's return on assets (ROA)?
Alzamend Neuro Inc (ALZN) had a return on assets of -421.9% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
How does Alzamend Neuro Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, Alzamend Neuro Inc (ALZN) held $711K in cash, cash equivalents and investments, and reported an operating cash outflow of $8.1M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Alzamend Neuro Inc's Piotroski F-Score?
Alzamend Neuro Inc (ALZN) has a Piotroski F-Score of 1 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Alzamend Neuro Inc's earnings high quality?
Alzamend Neuro Inc (ALZN) reported a net loss of $8.8M while operations used $8.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Alzamend Neuro Inc cover its interest payments?
Alzamend Neuro Inc (ALZN) reported an operating loss of $8.8M against $7K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.